Full Text
The Full Text of this article is available as a PDF (52.5 KB).
Footnotes
Suggested citation: Monath TP, Giesberg JA, Fierros EG. Yellow Fever Vaccine—Reply to S. Arya [letter]. Emerg Infect Dis [serial on the Internet]. 1999, Jun [date cited]. Available from http://www.cdc.gov/ncidod/EID/vol5no3/letters.htm#Monath
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Hacker U. T., Jelinek T., Erhardt S., Eigler A., Hartmann G., Nothdurft H. D., Endres S. In vivo synthesis of tumor necrosis factor-alpha in healthy humans after live yellow fever vaccination. J Infect Dis. 1998 Mar;177(3):774–778. doi: 10.1086/517806. [DOI] [PubMed] [Google Scholar]
- Monath T. P., Giesberg J. A., Fierros E. G. Does restricted distribution limit access and coverage of yellow fever vaccine in the United States? Emerg Infect Dis. 1998 Oct-Dec;4(4):698–702. doi: 10.3201/eid0404.980427. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Sanders E. J., Marfin A. A., Tukei P. M., Kuria G., Ademba G., Agata N. N., Ouma J. O., Cropp C. B., Karabatsos N., Reiter P. First recorded outbreak of yellow fever in Kenya, 1992-1993. I. Epidemiologic investigations. Am J Trop Med Hyg. 1998 Oct;59(4):644–649. doi: 10.4269/ajtmh.1998.59.644. [DOI] [PubMed] [Google Scholar]